Crucell Licenses Vaccine Technology to Merck

September 13, 2007
BioPharm International Editors

Merck&Co., Inc. (Whitehouse Station, NJ, www.merck.com) has exercised an option for the exclusive use of the PER.C6 technology, owned by Crucell N.V. (Leiden, The Netherlands, www.crucell.com), and an option for access to Crucell's AdVac vaccine technology in two infectious disease areas.

Merck & Co., Inc. (Whitehouse Station, NJ, www.merck.com) has exercised an option for the exclusive use of the PER.C6 technology, owned by Crucell N.V. (Leiden, The Netherlands, www.crucell.com), and an option for access to Crucell's AdVac vaccine technology in two infectious disease areas.

Under the terms of the agreement, Crucell also acquires rights to certain cell-line technology developed by Merck for the manufacturing of recombinant proteins. The option and the related rights to certain technology developed by Merck originate from the cross-license agreement executed in December 2006 between Crucell and Merck.

Related Content:

News